Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.
MRV Research
Induction of Systemic Immunity Following Treatment of Tumors with PV-10 Reported by Moffitt Cancer Center Researchers at American Association for Cancer Research Annual Meeting
Provectus Biopharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced today that a poster presentation detailing significant decrease in melanoma cells in patients’ injected tumors 7-14 days after intralesional PV-10 treatment that was accompanied by similar decrease in uninjected bystander tumors was presented April 6 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in San Diego, CA. These clinical and pathologic changes were accompanied by increases in important immune cell populations detected in the patients’ peripheral blood.
Study demonstrates efficacy, tolerability of vemurafenib in aggressive form of metastatic melanoma
The Lancet Oncology has published results from the largest ever trial of a single melanoma treatment. The open label safety study was conducted to assess the tolerability of Zelboraf® (vemurafenib), and featured 3,222 patients from across 44 countries. 246 of these patients were from the UK.
Drug is identified that could block the spread of melanoma
Cancer is at its most curable when it’s caught before it spreads. That’s especially true in the case of melanoma, where survival rates can be as high as 97 percent when caught early — and as low as 15 percent if it’s not. New research at Rockefeller has now identified a promising route to slowing or even preventing the metastasis of melanoma cells — something no current therapy can effectively accomplish.